Alberto Zaniboni

Summary

Affiliation: University of Brescia
Country: Italy

Publications

  1. pmc Targeting VEGF-VEGFR Pathway by Sunitinib in Peripheral Primitive Neuroectodermal Tumor, Paraganglioma and Epithelioid Hemangioendothelioma: Three Case Reports
    Tiziana Prochilo
    UO Oncologia, Fondazione Poliambulanza, Brescia, Mantua, Italy
    Case Rep Oncol 6:90-7. 2013
  2. ncbi Chemotherapeutic options for colorectal cancer patients with cardiovascular diseases
    Brunella Di Biasi
    UO di Oncologia, Fondazione Poliambulanza, Via Bissolati 57, 25124, Brescia, Italy
    Rev Recent Clin Trials 8:128-35. 2013
  3. doi FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study
    Alberto Zaniboni
    Medical Oncology Unit, Fondazione Poliambulanza, Via Bissolati 57, 25124, Brescia, Italy
    Cancer Chemother Pharmacol 69:1641-5. 2012
  4. pmc Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    BMC Cancer 9:303. 2009
  5. ncbi Neoadjuvant oxaliplatin-based chemotherapy for liver metastases from colorectal cancer. An Italian survey
    Alberto Zaniboni
    Oncologia Medica, Casa di Cura Poliambulanza, Brescia, Italy
    Tumori 91:383-7. 2005
  6. ncbi The emerging role of oxaliplatin in the treatment of gastric cancer
    A Zaniboni
    Fondazione Poliambulanza, Brescia, Italy
    J Chemother 17:656-62. 2005
  7. ncbi Non-small-cell lung cancer in the elderly
    Fausto Meriggi
    Oncology Department, Poliambulanza, Via Bissolati 57, 25124 Brescia, Italy
    Crit Rev Oncol Hematol 57:183-90. 2006
  8. ncbi Adjuvant therapy for stage II colon cancer: an elephant in the living room?
    A Zaniboni
    Oncologia Medica, Casa di Cura Poliambulanza, Brescia, Italy
    Ann Oncol 15:1310-8. 2004
  9. ncbi Anti-EGFR therapy in colorectal cancer: how to choose the right patient
    F Meriggi
    UO di Oncologia Medica, Fondazione Poliambulanza, Via Bissolati 54, 25124 Brescia, Italy
    Curr Drug Targets 10:1033-40. 2009
  10. doi Lack of a chemobrain effect for adjuvant FOLFOX chemotherapy in colon cancer patients. A pilot study
    Federica Andreis
    Department of Medical Oncology, Fondazione Poliambulanza, Via Bissolati 57, 25124, Brescia, Italy
    Support Care Cancer 21:583-90. 2013

Collaborators

Detail Information

Publications48

  1. pmc Targeting VEGF-VEGFR Pathway by Sunitinib in Peripheral Primitive Neuroectodermal Tumor, Paraganglioma and Epithelioid Hemangioendothelioma: Three Case Reports
    Tiziana Prochilo
    UO Oncologia, Fondazione Poliambulanza, Brescia, Mantua, Italy
    Case Rep Oncol 6:90-7. 2013
    ..On the basis of this preclinical rationale and the lack of effective treatments in pre-treated advanced stages of these rare diseases, we report our interesting experience of pPNET, PGL and EHE treatment with sunitinib...
  2. ncbi Chemotherapeutic options for colorectal cancer patients with cardiovascular diseases
    Brunella Di Biasi
    UO di Oncologia, Fondazione Poliambulanza, Via Bissolati 57, 25124, Brescia, Italy
    Rev Recent Clin Trials 8:128-35. 2013
    ....
  3. doi FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study
    Alberto Zaniboni
    Medical Oncology Unit, Fondazione Poliambulanza, Via Bissolati 57, 25124, Brescia, Italy
    Cancer Chemother Pharmacol 69:1641-5. 2012
    ....
  4. pmc Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    BMC Cancer 9:303. 2009
    ..Based on these findings we investigated the correlation between both FISH and CISH EGFR GCN and clinical outcome in K-RAS wild-type colorectal cancer treated with irinotecan-cetuximab...
  5. ncbi Neoadjuvant oxaliplatin-based chemotherapy for liver metastases from colorectal cancer. An Italian survey
    Alberto Zaniboni
    Oncologia Medica, Casa di Cura Poliambulanza, Brescia, Italy
    Tumori 91:383-7. 2005
    ..Only 10% to 25% of patients with liver metastases from colorectal cancer are suitable for resection. Methods for increasing the resectability of liver metastases are based on specific surgical techniques and neoadjuvant chemotherapy...
  6. ncbi The emerging role of oxaliplatin in the treatment of gastric cancer
    A Zaniboni
    Fondazione Poliambulanza, Brescia, Italy
    J Chemother 17:656-62. 2005
    ..This review focuses on the increasing amount of data concerning the clinical activity of oxaliplatin-based regimens in advanced gastric cancer...
  7. ncbi Non-small-cell lung cancer in the elderly
    Fausto Meriggi
    Oncology Department, Poliambulanza, Via Bissolati 57, 25124 Brescia, Italy
    Crit Rev Oncol Hematol 57:183-90. 2006
    ....
  8. ncbi Adjuvant therapy for stage II colon cancer: an elephant in the living room?
    A Zaniboni
    Oncologia Medica, Casa di Cura Poliambulanza, Brescia, Italy
    Ann Oncol 15:1310-8. 2004
    ..Putative prognostic markers for stage II patients, as well as the state-of-the-art of the adjuvant treatment in this setting, are reviewed in this paper...
  9. ncbi Anti-EGFR therapy in colorectal cancer: how to choose the right patient
    F Meriggi
    UO di Oncologia Medica, Fondazione Poliambulanza, Via Bissolati 54, 25124 Brescia, Italy
    Curr Drug Targets 10:1033-40. 2009
    ..In this article we will review the available clinical and experimental data potentially useful for a better patients' selection...
  10. doi Lack of a chemobrain effect for adjuvant FOLFOX chemotherapy in colon cancer patients. A pilot study
    Federica Andreis
    Department of Medical Oncology, Fondazione Poliambulanza, Via Bissolati 57, 25124, Brescia, Italy
    Support Care Cancer 21:583-90. 2013
    ..The combination of oxaliplatin, 5-fluorouracil, and leucovorin (the FOLFOX4 regimen) has emerged as the standard of care. This prospective study evaluates potential alterations in cognitive function in FOLFOX4-treated patients...
  11. ncbi Oxaliplatin-induced lung toxicity. Case report and review of the literature
    Tiziana Prochilo
    UO di Oncologia, Fondazione Poliambulanza, Brescia, Italy
    Curr Drug Saf 7:179-82. 2012
    ....
  12. ncbi Chemotherapy use at the end of life. A retrospective single centre experience analysis
    Federica Andreis
    UO di Oncologia Medica, Fondazione Poliambulanza, Brescia, Italy
    Tumori 97:30-4. 2011
    ..We compared our habits with other clinical patterns in medical oncology, calculating the temporal interval between the last chemotherapy administration and death of the patient...
  13. pmc Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study
    Federica Andreis
    UO di Oncologia Medica, Fondazione Poliambulanza, Via Bissolati 57, 25124 Brescia, Italy
    Health Qual Life Outcomes 8:40. 2010
    ..This monocentric cross sectional study is carried out to assess quality of life in colon cancer patients experienced skin side effects due to anti epidermal growth factor receptor inhibitors therapy...
  14. ncbi Cetuximab/irinotecan-chemotherapy in KRAS wild-type pretreated metastatic colorectal cancer: a pooled analysis and review of literature
    Sandro Barni
    Medical Oncology Unit, Oncology Department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047 Treviglio BG, Italia
    Rev Recent Clin Trials 8:101-9. 2013
    ..Here, the efficacy of this combination in patients with the KRAS wild-type gene as second- or further-line therapy is reviewed and data are collected in a pooled analysis...
  15. ncbi Phase II study of Taxol combined With ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer
    Alberto Zaniboni
    UO di Oncologia Medica, Casa di Cura Poliambulanza, Brescia, Italy
    Am J Clin Oncol 26:84-8. 2003
    ..Randomized studies both versus carboplatin-paclitaxel and other triplets are clearly warranted...
  16. pmc Cisplatin or not in advanced gastric cancer: a systematic review and meta-analysis
    Fausto Petrelli
    Medical Oncology Unit, Oncology Department, Azienda Ospedaliera Treviglio, Treviglio BG, Italy
    PLoS ONE 8:e83022. 2013
    ..The purpose of this meta-analysis study was to compare the efficacy of fchemotherapy with and without cisplatin in patients with advanced GC...
  17. ncbi Is there any role for sentinel node mapping in colorectal cancer staging? Personal experience and review of the literature
    C Codignola
    Department of General Surgery, Casa di Cura Poliambulanza, Brescia, Italy
    Jpn J Clin Oncol 35:645-50. 2005
    ..Pathologic techniques can successfully identify micrometastatic disease in lymph nodes, but they are not suitable for clinical routine use. We evaluated the role of sentinel node (SN) mapping in refining the staging of colorectal cancer...
  18. pmc Primary osteosarcoma of the breast: a case report
    Anna Rizzi
    Medical Oncology, Fondazione Poliambulanza, Via Bissolati 57, 25124 Brescia, Italy
    Case Rep Oncol Med 2013:858705. 2013
    ..Treatment follows the model of sarcomas affecting other locations and must be planned in a multidisciplinary fashion. Adjuvant chemotherapy should be considered for patients with tumors showing aggressive features...
  19. ncbi Mitomycin-C, adriamycin, 5-fluorouracil and leucovorin (L-FAM2) in the treatment of advanced gastric cancer: a phase II study
    A Zaniboni
    III Divisione di Medicina Generale, Spedali Civili, Brescia, Italy
    Tumori 77:160-3. 1991
    ..No other treatment-related death occurred. L-FAM2 is an effective combination for advanced gastric carcinoma. Further studies based on the association of leucovorin and 5-fluorouracil in combination with other active drugs are warranted...
  20. doi Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide
    Giordano Savelli
    Division of Nuclear Medicine, Carlo Poma Civic Hospital, Mantua, Italy
    Cancer 118:2915-24. 2012
    ..56 GigaBequerels bimonthly in patients with advanced stage, well differentiated neuroendocrine carcinomas...
  21. ncbi Fentanyl for breakthrough cancer pain: where are we?
    Fausto Meriggi
    Oncologia Medica, Fondazione Poliambulanza, Via Bissolati 57, 25124, Brescia, Italy
    Rev Recent Clin Trials 8:42-7. 2013
    ..The characteristics of the various formulations of transmucosal fentanyl used for BTcP and clinical data published in literature will be described in this review...
  22. pmc Management of potentially resectable colorectal cancer liver metastases
    Fausto Meriggi
    Fausto Meriggi, Paola Bertocchi, Alberto Zaniboni, Oncology Department, Istituto Ospedaliero Fondazione Poliambulanza, 25124 Brescia, Italy
    World J Gastrointest Surg 5:138-45. 2013
    ..Colorectal liver metastases represent a major challenge for oncologists and surgeons. In this review will be analyzed available data about assessment and management of the patients with potentially resectable colorectal liver metastases...
  23. ncbi Newer avenues for the treatment of leptomeningeal carcinomatosis
    Fausto Meriggi
    Oncology Department, Fondazione Poliambulanza, Via Bissolati 57, Brescia, Italy
    Cent Nerv Syst Agents Med Chem 11:38-44. 2011
    ..The treatment of LC remains controversial and no straightforward guidelines exist in the literature. It has a bad prognosis and inevitably fatal outcome despite aggressive therapy...
  24. ncbi [Current methods in the treatment of iatrogenic neutropenia]
    Fausto Meriggi
    UO di Oncologia Medica, Poliambulanza, Brescia
    Tumori 89:12-20. 2003
  25. ncbi The use of bevacizumab and trastuzumab beyond tumor progression: a new avenue in cancer treatment?
    F Meriggi
    Oncology Department, Fondazione Poliambulanza, Brescia, Italy
    Rev Recent Clin Trials 4:163-7. 2009
    ..The strength and the weakness of this innovative strategy, as well as the associated expense and toxicity issues will be discussed...
  26. ncbi Sequential methotrexate and 5-fluorouracil as second-line chemotherapy for advanced colorectal cancer patients pretreated with 5-fluorouracil and leucovorin: a GISCAD study
    A Zaniboni
    Servizio di Oncologia, Spedali Civili, Brescia, Italy
    J Chemother 8:82-4. 1996
    ..No WHO grade III-IV toxicities were reported. Despite the good tolerability, this combination of MTX, 5-FU and LV rescue has minimal activity in ACC after the failure of 5FU+LV-based chemotherapy...
  27. ncbi Fluorouracil, high-dose folinic acid, low-dose alpha-2b interferon and dipyridamole in the treatment of advanced colorectal cancer. A pilot study
    A Zaniboni
    Servizio di Oncologia, III Medicina, Spedali Civili, Brescia, Italy
    J Chemother 3:180-2. 1991
    ..Toxic side effects included oral mucositis (grade III-IV = 38%) and a generally mild flu-like syndrome. This regimen seems active and safe enough to be compared with the combination of fluorouracil and high-dose folinic acid...
  28. doi The impact of anemia on quality of life and hospitalisation in elderly cancer patients undergoing chemotherapy
    Laura Doni
    Medical Oncology Unit, AOU Careggi Hospital, Viale Pieraccini n 17, 50139 Firenze, FI, Italy
    Crit Rev Oncol Hematol 77:70-7. 2011
    ....
  29. ncbi Chemotherapy and anaesthetic drugs: too little is known
    Alberto Zaniboni
    Oncologia Medica, Casa di Cura Poliambulanza, Brescia, Italy
    Lancet Oncol 6:176-81. 2005
    ..More frequently, tumours are being managed in a multimodal integrated approach with medical, surgical, and radiotherapeutic aspects...
  30. ncbi Phase II trial of 5-fluorouracil and high-dose folinic acid in advanced renal cell cancer
    A Zaniboni
    Servizio di Oncologia, Spedali Civili, Brescia, Italy
    J Chemother 1:350-1. 1989
    ..No complete or partial remission was observed. Short-lasting stable disease occurred in 8 patients (median = 5 months, range 2-11). This combination does not need further evaluation in patients with RCC...
  31. ncbi Premarin priming before prednimustine, high-dose folinic acid and 5-fluorouracil as salvage chemotherapy for advanced breast cancer
    G Marini
    Servizio di Oncologia, Fondazione Beretta, Spedali Civili, Brescia, Italy
    Chemioterapia 7:130-2. 1988
    ..In spite of considerable activity as salvage regimen, these results do not seem better than those achieved in our Institute with high-dose folinic acid and 5-fluorouracil alone...
  32. ncbi The potential role of pemetrexed in gastrointestinal cancer
    F Meriggi
    Oncology Department, Fondazione Poliambulanza, Brescia, Italy
    Chemotherapy 54:1-8. 2008
    ....
  33. ncbi The emerging role of 5-fluorouracil and leucovorin in the treatment of advanced breast cancer. A review
    A Zaniboni
    III Divisione di Medicina Generale, Spedali Civili, Brescia, Italy
    J Chemother 1:330-7. 1989
    ..Current efforts to further improve the therapeutic index of this combination will also be briefly discussed...
  34. ncbi Oral etoposide as second-line chemotherapy for colorectal cancer: a GISCAD study. Gruppo Italiano Studio Carcinomi Apparato Digerente
    A Zaniboni
    Servizio di Oncologia, Spedali Civili, Brescia, Italy
    J Chemother 7:246-8. 1995
    ..Toxicity was substantial and mainly represented by myelosuppression and alopecia. Protracted administration of etoposide is inactive as second-line treatment of colorectal cancer...
  35. ncbi 5-Fluorouracil and dipyridamole in metastatic breast cancer: a pilot study
    A Zaniboni
    III Divisione Medicina Generale, Spedali Civili, Brescia, Italy
    J Chemother 1:266-8. 1989
    ..A different D schedule and the addition of folinic acid (FA) to 5-FU might provide better results and deserves further evaluation...
  36. ncbi Mitomycin-C and lonidamine as second-line therapy for colorectal cancer: a phase II study
    A Zaniboni
    Servizio di Oncologia, Spedali Civili, Brescia, Italy
    Tumori 81:435-7. 1995
    ..More experimental data about lonidamine are needed in order to design more effective regimens based on the combination of this interesting drug with other anticancer agents...
  37. ncbi The Renaissance of platinum-based chemotherapy for metastatic breast cancer
    F Meriggi
    Fondazione Poliambulanza, Oncologia Medica, Brescia, Italy
    J Chemother 20:551-60. 2008
    ..However, the definitive role of platinum compounds in the treatment of breast cancer is not yet well established and further trials are needed...
  38. ncbi Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC)
    Luigi Cavanna
    Department of Oncology, Hospital of Piacenza, Italy
    Am J Clin Oncol 29:371-5. 2006
    ..The goal of current study was to evaluate the efficacy and toxicity of Folfox-4 regimen in patients with A/MGC...
  39. ncbi Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma
    Roberto Labianca
    Unita Operativa di Oncologia Medica, Ospedali Riuniti, Bergamo, Italy RL
    J Natl Cancer Inst 96:750-8. 2004
    ..In a randomized clinical trial of patients with colon cancer, we compared the benefits of chemotherapy delivered by these routes individually or in combination...
  40. ncbi [ASCO 2006 Annual Meeting, Atlanta, June 2-6, 2006. Focus on gastrointestinal tumors]
    Andrea Bonetti
    Unità Operativa Complessa di Oncologia Medica Ospedale Mater Salutis, Legnago
    Tumori 92:suppl 10-43. 2006
  41. ncbi Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer
    Mario Scartozzi
    Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Universita Politecnica delle Marche, Ancona, Italy
    Tumori 92:384-8. 2006
    ..We evaluated the activity in terms of time to progression (TTP) of mitomycin C and capecitabine in patients with advanced colorectal cancer who progressed after 2 lines of chemotherapy...
  42. ncbi [Metastatic colorectal cancer: adjournments from ESMO 2006]
    Andrea Bonetti
    Dell Unità Operativa Complessa di Oncologia Medica, Ospedale Mater Salutis, Legnago, VR
    Tumori 92:1-12. 2006
  43. ncbi First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer
    Maria Giulia Zampino
    Medical Care Unit, Pathology Department, and Biostatistics Department, European Institute of Oncology, Milan, Italy
    Cancer 110:752-8. 2007
    ..Gefitinib combined with FOLFOX6 (oxaliplatin plus folinic acid and 5-fluorouracil) was tested as a first-line therapy...
  44. ncbi Molecular biology for stage II colorectal cancer: the jury is still out
    Stefano Cascinu
    J Clin Oncol 25:2861; author reply 2862-3. 2007
  45. ncbi Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy
    Mario Scartozzi
    Clinica di Oncologia Medica and Anatomia Patologica, Azienda Ospedaliera Ospedali Riuniti, Universita Politecnica delle Marche, Ancona, Italy
    J Clin Oncol 25:3930-5. 2007
    ..The aim of our analysis was to investigate a correlation between NF-kB expression, response rate, time to progression, and survival in advanced colorectal cancer patients receiving cetuximab and irinotecan...
  46. doi Molecular signature detection of circulating tumor cells using a panel of selected genes
    Annalisa Gervasoni
    Centro di Ricerca E Menni, Fondazione Poliambulanza Istituto Ospedaliero, Via Bissolati, 57, I 25124 Brescia, Italy
    Cancer Lett 263:267-79. 2008
    ....
  47. ncbi Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial
    Stefano Cascinu
    Polytechnic University of Marche Riuniti Hospital Umberto I GM Lancisi G Salesi of Ancona, 60020 Ancona, Italy
    Lancet Oncol 9:39-44. 2008
    ..The aim of this study was to assess the activity and feasibility of a combination of cetuximab with gemcitabine and cisplatin compared with use of gemcitabine and cisplatin alone for the treatment of advanced pancreatic cancer...